Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ p16INK4a Monoclonal Antibody (1D7D2)

Mouse Monoclonal Antibody

Supplier:  Invitrogen™ MA517054

Catalog No. PIMA517054


Only null left
Add to Cart

Description

Description

MA5-17054 targets CDKN2A in FACS, IHC, indirect ELISA, and WB applications and shows reactivity with Human samples. The MA5-17054 immunogen is purified recombinant fragment of human CDKN2A (amino acids: 1-156) expressed in E. Coli. MA5-17054 detects CDKN2A which has a predicted molecular weight of approximately 16.5kDa.

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

p16INK4a
Monoclonal
Conc. not determined
ascites with 0.03% sodium azide
P42771, Q8N726
CDKN2A
Purified recombinant fragment of human CDKN2A (amino acids: 1-156) expressed in E. Coli.
RUO
1029
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Liquid
ELISA, Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry
1D7D2
Unconjugated
CDKN2A
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19>ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Mouse
100 μL
Primary
Human
Antibody
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.